^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN NSCLC Panel recommends single-agent pembrolizumab (category 1; preferred) as a first-line therapy option for eligible patients with advanced nonsquamous or squamous NSCLC, PD-L1 expression levels of 50% or more…
Secondary therapy:
albumin-bound paclitaxel + carboplatin; cisplatin + pemetrexed; pemetrexed + carboplatin;
Source:
Title:
PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer
Published date:
08/26/2021
Excerpt:
...high PD-L1 TPS was significantly associated with improved overall survival by a median OS difference of 8.4 months (p <0.001)….Among NSCLC patients treated with 1L pembrolizumab, high PD-L1 TPS is associated with OS among patients with nonsquamous NSCLC, but not among patients with squamous NSCLC.
DOI:
10.1016/j.jtho.2021.07.032
Source:
Title:
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
Published date:
07/21/2022
Excerpt:
...very high PD-L1 expression was associated with better survival for patients with non-squamous histology (HR 0.78; 95% CI 0.66-0.92) but not in those with a squamous cell histology/histology….In this cohort study of aNSCLC patients with PD-L1 expression ≥ 50% treated with first line pembrolizumab, having a PD-L1 expression ≥ 90% was associated with better overall survival ([IPW hazard ratio 0.79, 95% CI 0.69-0.91] and median survival [15.84 months (very high -PD-L1 expression [≥ 90%])...
DOI:
10.1016/j.cllc.2022.07.003
Source:
Title:
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
Published date:
10/16/2021
Excerpt:
...we aimed to evaluate the efficacy and toxicity of first-line single-agent ICIs versus ICI combinations for advanced NSCLC patients with PD-L1 ≥ 50%....The results showed that chemotherapy plus ICIs significantly improved PFS and ORR compared to chemotherapy, and sinti-chemo (HR: 0.31, 95% CI: 0.20-0.49) and pembro-chemo (OR: 4.2, 95% CI: 2.6-6.7) ranked first....In the subgroup analysis of histological type, pembro-chemo and sinti-chemo showed the best benefit of PFS in squamous and nonsquamous NSCLC, respectively...
Secondary therapy:
Chemotherapy
DOI:
10.1007/s00262-021-03089-x
Source:
Title:
108P - Real-World Time on Treatment (rwToT) Analysis for First-Line Pembrolizumab Combination Therapy in Advanced Nonsquamous NSCLC
Published date:
03/17/2021
Excerpt:
Our aim was to evaluate rwToT with first-line pembro combo in patients with advanced nonsquamous NSCLC….In the PD-L1 TPS ≥50% cohort, 26% of patients remained on pembrolizumab at 2 years….A considerable proportion of patients remained on pembrolizumab at 2 years, suggesting long-term benefit.
Source:
Title:
1328P - Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices
Published date:
09/14/2020
Excerpt:
Outcomes from this real-world data analysis show clinical benefits with CPP in elderly patients with metastatic nonsquamous NSCLC and the benefit increases with higher levels of PD-L1 score.
Secondary therapy:
carboplatin + pemetrexed
